IE52296B1 - Veterinary medicament based on benzoquinolizine carboxylic acids and their derivatives - Google Patents
Veterinary medicament based on benzoquinolizine carboxylic acids and their derivativesInfo
- Publication number
- IE52296B1 IE52296B1 IE712/80A IE71280A IE52296B1 IE 52296 B1 IE52296 B1 IE 52296B1 IE 712/80 A IE712/80 A IE 712/80A IE 71280 A IE71280 A IE 71280A IE 52296 B1 IE52296 B1 IE 52296B1
- Authority
- IE
- Ireland
- Prior art keywords
- oxo
- quinolizine
- methyl
- benzo
- carboxylic acid
- Prior art date
Links
- SWWBKIRNVOWLRS-UHFFFAOYSA-N 4h-benzo[a]quinolizine-1-carboxylic acid Chemical class C1=CC=C2C3=C(C(=O)O)C=CCN3C=CC2=C1 SWWBKIRNVOWLRS-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 239000003814 drug Substances 0.000 title claims description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- -1 halegeno Chemical group 0.000 claims abstract description 9
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 150000003254 radicals Chemical group 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 230000001079 digestive effect Effects 0.000 claims abstract description 3
- 210000002249 digestive system Anatomy 0.000 claims abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 3
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 230000000813 microbial effect Effects 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 6
- KASNWJJVSFNDJM-UHFFFAOYSA-N 1-azatricyclo[7.3.1.05,13]trideca-3,5,7,9(13),10-pentaene-3-carboxylic acid Chemical compound C1=CCN2CC(C(=O)O)=CC3=CC=CC1=C32 KASNWJJVSFNDJM-UHFFFAOYSA-N 0.000 claims description 3
- 125000005605 benzo group Chemical group 0.000 claims description 3
- MPBKXLYEVJVZEX-UHFFFAOYSA-M sodium 7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylate Chemical compound [Na+].C1CC(C)N2C=C(C([O-])=O)C(=O)C3=C2C1=CC(F)=C3 MPBKXLYEVJVZEX-UHFFFAOYSA-M 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- YBOMULLBDZBBKN-UHFFFAOYSA-N 10-acetamido-6,7-dihydro-5-methyl-1-oxo-1h,5h-benzo[ij]quinolizine-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC=C3NC(C)=O YBOMULLBDZBBKN-UHFFFAOYSA-N 0.000 claims 1
- IAKNLKLKKBPMHN-UHFFFAOYSA-N 4h-quinolizine-2-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CCN21 IAKNLKLKKBPMHN-UHFFFAOYSA-N 0.000 claims 1
- PPWSMSAQXQFEMG-UHFFFAOYSA-N 6,8,12-trimethyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(C)C=C3C PPWSMSAQXQFEMG-UHFFFAOYSA-N 0.000 claims 1
- XMLKZFJCWUKBGF-UHFFFAOYSA-N 8-chloro-5-methyl-6,7-dihydro-1-oxo-1h,5h-benzo-[ij]quinolizine-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(Cl)C=C3 XMLKZFJCWUKBGF-UHFFFAOYSA-N 0.000 claims 1
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N tetrahydroquinoline Natural products C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- PSZAEHPBBUYICS-UHFFFAOYSA-N 2-methylidenepropanedioic acid Chemical group OC(=O)C(=C)C(O)=O PSZAEHPBBUYICS-UHFFFAOYSA-N 0.000 description 1
- CGVGKYQXTFEGSB-UHFFFAOYSA-N 6,7-dihydro-4H-benzo[a]quinolizine-2-carboxylic acid Chemical class C=1C(=CCN2CCC3=C(C=12)C=CC=C3)C(=O)O CGVGKYQXTFEGSB-UHFFFAOYSA-N 0.000 description 1
- XMZFEGSYODZXFT-UHFFFAOYSA-N 6h-quinolizine-4-carboxylic acid Chemical compound C1=CCN2C(C(=O)O)=CC=CC2=C1 XMZFEGSYODZXFT-UHFFFAOYSA-N 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001415288 Coccidae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001443706 Papio papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940041667 oral paste Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21723/79A IT1111918B (it) | 1979-04-10 | 1979-04-10 | Medicamento veterinario a base di acidi benzochinolizin carbossilici e loro derivati |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE800712L IE800712L (en) | 1980-10-10 |
| IE52296B1 true IE52296B1 (en) | 1987-09-02 |
Family
ID=11185937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE712/80A IE52296B1 (en) | 1979-04-10 | 1980-04-09 | Veterinary medicament based on benzoquinolizine carboxylic acids and their derivatives |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU5728280A (ref) |
| FR (1) | FR2453647A1 (ref) |
| GB (1) | GB2049420A (ref) |
| IE (1) | IE52296B1 (ref) |
| IT (1) | IT1111918B (ref) |
| NZ (1) | NZ193374A (ref) |
| ZA (1) | ZA802088B (ref) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4380543A (en) * | 1981-11-06 | 1983-04-19 | Riker Laboratories, Inc. | Antimicrobial 8-cyano-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acids |
| HU206975B (en) * | 1991-03-14 | 1993-03-01 | Reanal Finomvegyszergyar | Process for producing granulation and veterinary composition comprising water-soluble flumequine complex |
| HUP9601361A3 (en) * | 1996-05-21 | 1999-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing optically active compounds |
| HUP9601362A3 (en) * | 1996-05-21 | 1999-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing optically active compounds |
-
1979
- 1979-04-10 IT IT21723/79A patent/IT1111918B/it active
-
1980
- 1980-04-09 NZ NZ193374A patent/NZ193374A/xx unknown
- 1980-04-09 IE IE712/80A patent/IE52296B1/en not_active IP Right Cessation
- 1980-04-09 AU AU57282/80A patent/AU5728280A/en not_active Withdrawn
- 1980-04-09 ZA ZA00802088A patent/ZA802088B/xx unknown
- 1980-04-10 FR FR8008061A patent/FR2453647A1/fr active Granted
- 1980-04-10 GB GB8011882A patent/GB2049420A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2453647B1 (ref) | 1983-12-23 |
| AU5728280A (en) | 1980-10-16 |
| IT1111918B (it) | 1986-01-13 |
| IE800712L (en) | 1980-10-10 |
| NZ193374A (en) | 1982-12-07 |
| IT7921723A0 (it) | 1979-04-10 |
| FR2453647A1 (fr) | 1980-11-07 |
| GB2049420A (en) | 1980-12-31 |
| ZA802088B (en) | 1981-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200876B2 (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| US3884906A (en) | 2,2-Methylendeiphenols processes of preparing the same, and methods of treating therewith mammals infected with internal parasites | |
| US5281596A (en) | Antibacterial drugs for fish | |
| GB2049420A (en) | Veterinary medicament based on benxoquinolizine carboxylic acids and their derivatives | |
| DE2505474A1 (de) | Substituierte pyrido eckige klammer auf 1,2,3-de eckige klammer zu -1,4-benzoxazine | |
| JPH0717609B2 (ja) | ノルフロキサシンの水溶性付加物 | |
| US4163801A (en) | Treatment of animals with 2,6-bis(2-hydroxybenzyl)phenols to eradicate trematodes | |
| US3984548A (en) | Substituted pyrido[1,2,3,-de]-1,4-benzoxazines as bactericides | |
| CN111329864A (zh) | 喹唑酮类化合物及其用途 | |
| DE69519581T2 (de) | Guanidylmethyl cyclohexancarbonsäure ester derivate | |
| US4285972A (en) | Method of treating scours | |
| Usubillaga et al. | Anti-snake venom effect of Aristolochia odoratissima L. aqueous extract on mice | |
| US4282390A (en) | 2,6-Benzyl substituted phenols | |
| US3993760A (en) | Pyrazinoisoquinolines as anthelmintic agents | |
| DE3104282C2 (ref) | ||
| Schnitzer et al. | Chemical and toxicological studies on phenothiazine | |
| US3015606A (en) | Dinitrobenzamide remedies for coccidiosis and salmonella infections | |
| US4031249A (en) | Compositions containing certain 2,4-halo-6-nitrophenols or derivatives thereof and methods for using same to eradicate internal parasites in warm-blooded animals | |
| US4404189A (en) | Synergistic antimicrobial compositions | |
| Levy et al. | The use of DPPD (N, N1-diphenyl-p-phenylediamine) as an anti-inflammatory agent | |
| DE2500490A1 (de) | Derivate von 2-substit.-thiazol-5- carbonsaeurehydraziden, verfahren zu ihrer herstellung sowie diese enthaltende pharmazeutische zubereitungen | |
| JPS5533453A (en) | Preventive and remedy for infectious disease of fish | |
| DK174984B1 (da) | Anvendelse af quinolinderivatrer, deres salte eller hydrater til fremstilling af antibakterielle medikamenter til fisk | |
| US4192886A (en) | Methods for treating gastrointestinal disease | |
| AU7322396A (en) | Pyrido (3,2,1-ij)-1,3,4-benzoxadiazine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |